StockWatch
·
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Quarterly ResultMay 15, 2026, 04:13 PM

Q/C Technologies Q1 Net Loss Attributable to Common Stockholders $(1.53)M

AI Summary

Q/C Technologies reported a net loss attributable to common stockholders of $(1,528,448) for the first quarter of 2026, with basic and diluted net loss per common share improving to $(0.19). The company remains pre-revenue, focusing on investment income, and saw a significant decrease in research and development expenses. These results reflect the company's ongoing transition in its business model towards energy-efficient blockchain, cryptocurrency infrastructure, and quantum-class laser-based computing.

Key Highlights

  • Net Loss Attributable to Common Stockholders was $(1,528,448) for the three months ended March 31, 2026.
  • Basic and diluted net loss per common share improved to $(0.19) for Q1 2026 from $(0.36) in Q1 2025.
  • Cash and Cash Equivalents increased to $1,127,619 as of March 31, 2026, from $986,996 at December 31, 2025.
  • Total Assets decreased to $38,291,383 as of March 31, 2026, from $41,166,096 at December 31, 2025.
  • Net cash used in operating activities was $(3,286,563) for the three months ended March 31, 2026.
  • Research and Development Expenses decreased to $510,534 for Q1 2026 from $1,545,513 in Q1 2025.
  • The company reported no product revenue for the three months ended March 31, 2026 and 2025.